Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: A new look at hallmarks of breast cancer - PubMed (original) (raw)
Review
. 2019 Jul;234(7):10080-10100.
doi: 10.1002/jcp.27941. Epub 2018 Dec 10.
Affiliations
- PMID: 30537129
- DOI: 10.1002/jcp.27941
Review
Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: A new look at hallmarks of breast cancer
Rasoul Abdollahzadeh et al. J Cell Physiol. 2019 Jul.
Abstract
Breast cancer (BC) is the most frequently occurring malignancy in women worldwide. Despite the substantial advancement in understanding the molecular mechanisms and management of BC, it remains the leading cause of cancer death in women. One of the main reasons for this obstacle is that we have not been able to find the Achilles heel for the BC as a highly heterogeneous disease. Accumulating evidence has revealed that noncoding RNAs (ncRNAs), play key roles in the development of BC; however, the involving of complex regulatory interactions between the different varieties of ncRNAs in the development of this cancer has been poorly understood. In the recent years, the newly discovered mechanism in the RNA world is "competing endogenous RNA (ceRNA)" which proposes regulatory dialogues between different RNAs, including long ncRNAs (lncRNAs), microRNAs (miRNAs), transcribed pseudogenes, and circular RNAs (circRNAs). In the latest BC research, various studies have revealed that dysregulation of several ceRNA networks (ceRNETs) between these ncRNAs has fundamental roles in establishing the hallmarks of BC development. And it is thought that such a discovery could open a new window for a better understanding of the hidden aspects of breast tumors. Besides, it probably can provide new biomarkers and potential efficient therapeutic targets for BC. This review will discuss the existing body of knowledge regarding the key functions of ceRNETs and then highlights the emerging roles of some recently discovered ceRNETs in several hallmarks of BC. Moreover, we propose for the first time the "ceRnome" as a new term in the present article for RNA research.
Keywords: breast cancer; ceRNA; ceRNET; ceRnome; ncRNAs.
© 2018 Wiley Periodicals, Inc.
Similar articles
- Competing Endogenous RNA Networks in Glioma.
Cen L, Liu R, Liu W, Li Q, Cui H. Cen L, et al. Front Genet. 2021 Apr 29;12:675498. doi: 10.3389/fgene.2021.675498. eCollection 2021. Front Genet. 2021. PMID: 33995499 Free PMC article. Review. - Identification of dysregulated competing endogenous RNA networks in glioblastoma: A way toward improved therapeutic opportunities.
Rahnama S, Bakhshinejad B, Farzam F, Bitaraf A, Ghazimoradi MH, Babashah S. Rahnama S, et al. Life Sci. 2021 Jul 15;277:119488. doi: 10.1016/j.lfs.2021.119488. Epub 2021 Apr 19. Life Sci. 2021. PMID: 33862117 Review. - Roles of ncRNAs as ceRNAs in Gastric Cancer.
Ye J, Li J, Zhao P. Ye J, et al. Genes (Basel). 2021 Jul 2;12(7):1036. doi: 10.3390/genes12071036. Genes (Basel). 2021. PMID: 34356052 Free PMC article. Review. - Biomarker potential of competing endogenous RNA networks in Polycystic Ovary Syndrome (PCOS).
Heidarzadehpilehrood R, Pirhoushiaran M. Heidarzadehpilehrood R, et al. Noncoding RNA Res. 2024 Jan 17;9(2):624-640. doi: 10.1016/j.ncrna.2024.01.002. eCollection 2024 Jun. Noncoding RNA Res. 2024. PMID: 38571815 Free PMC article. Review. - Regulatory and therapeutic implications of competing endogenous RNA network in breast cancer progression and metastasis: A review.
Saranya I, Dharshini VS, Akshaya RL, Subhashini PS, Selvamurugan N. Saranya I, et al. Int J Biol Macromol. 2024 May;266(Pt 2):131075. doi: 10.1016/j.ijbiomac.2024.131075. Epub 2024 Mar 24. Int J Biol Macromol. 2024. PMID: 38531528 Review.
Cited by
- Competing Endogenous RNA Networks in Glioma.
Cen L, Liu R, Liu W, Li Q, Cui H. Cen L, et al. Front Genet. 2021 Apr 29;12:675498. doi: 10.3389/fgene.2021.675498. eCollection 2021. Front Genet. 2021. PMID: 33995499 Free PMC article. Review. - LncRNA NOP14-AS1 Promotes Tongue Squamous Cell Carcinoma Progression by Targeting MicroRNA-665/HMGB3 Axis.
Li J, Fan S, Liu S, Yang G, Jin Q, Xiao Z. Li J, et al. Cancer Manag Res. 2021 Mar 26;13:2821-2834. doi: 10.2147/CMAR.S293322. eCollection 2021. Cancer Manag Res. 2021. PMID: 33814931 Free PMC article. Retracted. - DGCR5 Promotes Gallbladder Cancer by Sponging MiR-3619-5p via MEK/ERK1/2 and JNK/p38 MAPK Pathways.
Liu S, Chu B, Cai C, Wu X, Yao W, Wu Z, Yang Z, Li F, Liu Y, Dong P, Gong W. Liu S, et al. J Cancer. 2020 Jul 11;11(18):5466-5477. doi: 10.7150/jca.46351. eCollection 2020. J Cancer. 2020. PMID: 32742494 Free PMC article. - Machine Learning-Based Integration Develops a Pyroptosis-Related lncRNA Model to Enhance the Predicted Value of Low-Grade Glioma Patients.
Wu J, Lu L, Wang C, Jiang F. Wu J, et al. J Oncol. 2022 May 19;2022:8164756. doi: 10.1155/2022/8164756. eCollection 2022. J Oncol. 2022. PMID: 35646114 Free PMC article. - GLUT1 Regulates the Tumor Immune Microenvironment and Promotes Tumor Metastasis in Pancreatic Adenocarcinoma via ncRNA-mediated Network.
Li F, He C, Yao H, Liang W, Ye X, Ruan J, Lin L, Zou J, Zhou S, Huang Y, Li Y, Chen S, Huang K, Lian G, Chen S. Li F, et al. J Cancer. 2022 May 13;13(8):2540-2558. doi: 10.7150/jca.72161. eCollection 2022. J Cancer. 2022. PMID: 35711842 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical